UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-08089 DANAHER CORPORATION (Exact name of registrant as specified in its charter) Delaware 59-19 ...

ITT Inc.’s (ITT) fourth-quarter 2023 adjusted earnings (excluding 3 cents from non-recurring items) of $1.34 per share matched the Zacks Consensus Estimate. The bottom line jumped 3.9% year over year, owing to an increase in sales across each of the segments.Total revenues of $829.1 million beat the consensus estimate of $812 million. The top line increased 7% year over year, owing to higher Friction original equipment volumes in the Motion Technologies segment, pricing actions in the Connect & Control Tech ...

Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development, and help ensure patient safety WASHINGTON, Feb. 5, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today launched a strategic collaboration with Cincinnati Children's Hospital Medical Center, wi ...

Danaher Corporation’s (DHR) fourth-quarter 2023 adjusted earnings (excluding 59 cents from non-recurring items) of $2.09 per share surpassed the Zacks Consensus Estimate of $1.90. The bottom line declined 17.7% year over year.Danaher’s net sales of $6,405 million outperformed the consensus estimate of $5,990 million. However, the metric declined 10.2% year over year due to a decrease in sales of COVID-related products and weakness in the Biotechnology and Diagnostics segments.Organic sales in the quarter de ...

Danaher Corporation (NYSE:DHR) Q4 2023 Earnings Conference Call January 30, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer Blair - President and CEO Matt McGrew - EVP and CFO Conference Call Participants Dan Brennan - TD Cowen Vijay Kumar - Evercore ISI Scott Davis - Melius Research Michael Ryskin - Bank of America Rachel Vatnsdal - JPMorgan Puneet Souda - Leerink Partners Operator Good morning. My name is Todd and I will be your conference facilitator this morning. At this time, I woul ...

For the quarter ended December 2023, Danaher (DHR) reported revenue of $6.41 billion, down 23.5% over the same period last year. EPS came in at $2.09, compared to $2.87 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $5.99 billion, representing a surprise of +6.93%. The company delivered an EPS surprise of +10.00%, with the consensus EPS estimate being $1.90.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street e ...

Danaher Corporation Fourth Quarter 2023 Earnings Release ...

Danaher (DHR) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.90 per share. This compares to earnings of $2.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10%. A quarter ago, it was expected that this industrial and medical device maker would post earnings of $1.83 per share when it actually produced earnings of $2.02, delivering a surprise of 10.38%.Over the last four quarte ...

Investors are always looking for stocks that are poised to beat at earnings season and Danaher Corporation (DHR) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Danaher is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good in ...

Danaher Corporation (DHR) is scheduled to release fourth-quarter 2023 results on Jan 30, before market open.The company’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 8.5%. In the last reported quarter, its earnings of $2.02 per share beat the Zacks Consensus Estimate of $1.83 by 10.4%.Image Source: Zacks Investment ResearchIn the past three months, DHR’s shares have gained 21% compared with the industry’s growth of 13.6%.Let’s see how thi ...